Q1 2022

Filed May 12, 2022 · 10-Q · 42 days after period end · 0001564590-22-019685

Q1 2022 · 10-Q

Revenue

$3.11M

+28.6% vs Q1 2021

Net Income

-$7.70M

N/M vs Q1 2021

EPS Diluted

-$1.55

N/M vs Q1 2021

Operating Income-$5,611,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	$3.11M	$2.42M	—	$7.02M
Net Income	-$7.70M	-$7.26M	$2.90M	-$12.02M
EPS Diluted	-$1.55	-$1.64	$0.89	-$7.64

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR